1. [CASE 1 — QUESTION 1] A 64-year-old man with end-stage renal disease on hemodialysis is admitted with fever, hypotension, and a tunneled dialysis catheter that was placed 6 weeks ago. Blood cultures drawn on admission grow Klebsiella pneumoniae within 16 hours. Carbapenemase PCR is sent urgently and returns positive for KPC (Klebsiella pneumoniae carbapenemase). The isolate is resistant to all tested carbapenems, piperacillin-tazobactam, and ceftriaxone. Susceptibility testing confirms susceptibility to ceftazidime-avibactam and meropenem-vaborbactam. The infectious disease team is selecting definitive therapy. The KPC enzyme in this isolate is confirmed to be wild-type with no active site mutations. Which of the following best justifies selecting ceftazidime-avibactam as initial definitive therapy for this KPC-CRE bacteremia, and identifies the mechanism by which avibactam enables activity against KPC?

• A) Ceftazidime-avibactam is preferred over meropenem-vaborbactam because ceftazidime has higher affinity for KPC-producing Klebsiella PBP2 than meropenem at the concentrations achieved with standard dosing, making it more bactericidal regardless of which inhibitor is paired with the beta-lactam partner
• B) Ceftazidime-avibactam is preferred because avibactam irreversibly inactivates KPC through a mechanism-based suicide inhibitor reaction that permanently destroys the enzyme active site, preventing re-emergence of enzymatic activity during therapy; vaborbactam's reversible mechanism allows KPC to regenerate activity between doses
• C) Ceftazidime-avibactam is an appropriate choice for KPC-CRE because avibactam is a DBO (diazabicyclooctane) inhibitor that forms a reversible covalent carbamyl ester with the catalytic serine of KPC — a class A serine carbapenemase — blocking enzymatic hydrolysis of ceftazidime and allowing it to reach its PBP targets; both ceftazidime-avibactam and meropenem-vaborbactam are guideline-supported options for KPC-CRE, and initial selection may be guided by institutional susceptibility data and availability
• D) Ceftazidime-avibactam must be used rather than meropenem-vaborbactam because this patient is on hemodialysis, and vaborbactam is removed by hemodialysis to a degree that makes standard dosing pharmacokinetically inadequate; ceftazidime-avibactam's components are not removed by hemodialysis at all
• E) Ceftazidime-avibactam is preferred because KPC-producing Klebsiella strains universally upregulate MexAB-OprM efflux pumps that export meropenem from the periplasm before it can engage PBP targets, rendering meropenem-vaborbactam inactive regardless of vaborbactam's KPC inhibitory activity

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Ceftazidime-avibactam is initiated and the patient initially improves — fever resolves and inflammatory markers fall over days 3 through 5. On day 7 he develops recurrent bacteremia. Repeat blood cultures grow the same Klebsiella pneumoniae, now reported as resistant to ceftazidime-avibactam with an MIC (minimum inhibitory concentration) substantially higher than the baseline isolate. Molecular testing of the new isolate identifies a D179Y point mutation in the KPC enzyme. The infectious disease team must explain what happened and select salvage therapy. Which of the following best explains the mechanism of this on-therapy resistance and identifies the most appropriate next agent?

• A) The D179Y mutation alters residues in the KPC active site that contact avibactam's DBO scaffold, destabilizing the covalent carbamyl ester complex between avibactam and KPC's catalytic serine and thereby reducing the duration of enzyme inhibition; meropenem-vaborbactam is the appropriate salvage agent because vaborbactam's boronic acid mechanism contacts overlapping but non-identical active site residues and retains inhibitory activity against D179Y KPC variants in most cases
• B) The D179Y mutation upregulates expression of a second, avibactam-insensitive class B metallo-beta-lactamase gene that was previously silenced; switching to aztreonam-avibactam provides appropriate coverage because aztreonam is stable to class B enzymes, and avibactam continues to inhibit the original class A KPC
• C) The D179Y mutation converts KPC from a class A serine enzyme to a class B zinc-dependent enzyme by incorporating a zinc-binding histidine at residue 179; neither avibactam nor vaborbactam inhibits the resulting metalloenzyme, and aztreonam-avibactam becomes the only effective option
• D) The D179Y mutation expands KPC's substrate spectrum to include aztreonam in addition to carbapenems; cefiderocol is therefore the recommended salvage agent because its siderophore uptake mechanism bypasses all known KPC variants and delivers drug to PBP3 before periplasmic KPC can access the beta-lactam ring
• E) The D179Y mutation causes KPC to be expressed at 100-fold higher levels through promoter upregulation; the resistance is quantitative rather than qualitative, and doubling the ceftazidime-avibactam dose overcomes the higher enzyme burden by maintaining free avibactam concentrations above the elevated Ki (inhibitor constant) of the overexpressed wild-type KPC

3. [CASE 1 — QUESTION 3] Continuing with the same patient. Meropenem-vaborbactam is initiated and the patient begins to improve again. A pharmacy student on rotation asks the attending to explain the clinical trial evidence supporting meropenem-vaborbactam for KPC-CRE, and also asks whether the same regimen would be expected to work if the patient had instead presented with NDM-producing Klebsiella pneumoniae. Which of the following best answers both parts of the student's question?

• A) The TANGO II trial (a randomized controlled trial of meropenem-vaborbactam versus best available therapy for carbapenem-resistant infections) demonstrated non-inferiority of meropenem-vaborbactam to best available therapy; meropenem-vaborbactam would be equally effective against NDM-CRE because vaborbactam's boronic acid mechanism provides broad-spectrum inhibition of all four Ambler beta-lactamase classes including class B metallo-beta-lactamases
• B) The TANGO II trial demonstrated superiority of meropenem-vaborbactam over best available therapy specifically for KPC-CRE infections; meropenem-vaborbactam would also be effective against NDM-CRE because meropenem itself is partially stable to NDM hydrolysis at the extended infusion concentrations used in the TANGO II protocol
• C) Meropenem-vaborbactam has not been evaluated in a randomized clinical trial; its approval was based entirely on pharmacokinetic-pharmacodynamic modeling and compassionate use case series; it would not be expected to work against NDM-CRE because vaborbactam's narrow class A-only inhibitory spectrum cannot protect meropenem from NDM hydrolysis
• D) The TANGO II trial (a randomized controlled trial of meropenem-vaborbactam versus best available therapy for KPC-CRE and other carbapenem-resistant infections) demonstrated superior 28-day outcomes with meropenem-vaborbactam over best available therapy for KPC-CRE; meropenem-vaborbactam would NOT be expected to work against NDM-CRE because vaborbactam is a serine beta-lactamase inhibitor (boronic acid mechanism targeting the class A/C catalytic serine) and NDM is a class B zinc-dependent metallo-beta-lactamase with no catalytic serine for vaborbactam to target
• E) The TANGO II trial demonstrated that meropenem-vaborbactam was superior to ceftazidime-avibactam for KPC-CRE in a head-to-head comparison; meropenem-vaborbactam would not work for NDM-CRE, but aztreonam can be added to any meropenem-vaborbactam regimen to provide NDM coverage through aztreonam's independent siderophore uptake pathway that bypasses NDM hydrolysis

4. [CASE 1 — QUESTION 4] Continuing with the same patient. The patient is responding well to meropenem-vaborbactam. The clinical pharmacist raises a concern about pharmacokinetic management in this hemodialysis-dependent patient. The pharmacist notes that both meropenem and vaborbactam are primarily renally eliminated with low protein binding, and that standard dosing for meropenem-vaborbactam is designed for patients with normal renal function. Which of the following best describes the pharmacokinetic principle that requires dose adjustment and special timing considerations for meropenem-vaborbactam in this hemodialysis patient?

• A) Meropenem-vaborbactam dose adjustment is unnecessary in hemodialysis because the dialysis membrane removes both drug components at a rate that precisely mimics normal renal clearance, effectively restoring normal pharmacokinetics; no supplemental dosing or timing adjustments relative to dialysis sessions are required
• B) Both meropenem and vaborbactam have low protein binding and are primarily renally eliminated; in a hemodialysis patient, residual renal clearance is negligible and standard dosing produces drug accumulation with potential toxicity; both components are also significantly removed by hemodialysis sessions, requiring dose adjustment to account for reduced interdialytic clearance and supplemental dosing after dialysis sessions to replace drug removed during the dialysis run
• C) Only meropenem requires dose adjustment in hemodialysis; vaborbactam is metabolized hepatically to an inactive metabolite that is excreted in bile regardless of renal function, so vaborbactam dosing remains unchanged while only the meropenem component is reduced proportionally to the degree of renal impairment
• D) Meropenem-vaborbactam requires dose escalation rather than reduction in hemodialysis patients because dialysis-associated inflammatory cytokines upregulate CYP3A4 in hepatocytes, accelerating meropenem metabolism and reducing its serum half-life to less than 30 minutes; higher doses are needed to maintain time above MIC between dialysis sessions
• E) Dose adjustment for meropenem-vaborbactam in hemodialysis is guided solely by vaborbactam accumulation; meropenem is not dialyzable and accumulates to toxic levels between sessions, requiring extended-interval dosing of the meropenem component; vaborbactam is freely dialyzable and its dose is timed to begin immediately after each dialysis session ends

5. [CASE 2 — QUESTION 1] A 71-year-old woman undergoes elective resection of a posterior fossa meningioma. On postoperative day 4 she develops fever, nuchal rigidity, and photophobia. Lumbar puncture shows CSF (cerebrospinal fluid) pleocytosis with gram-negative rods on Gram stain. Her allergy record documents anaphylaxis to penicillin (hives and laryngeal edema after amoxicillin administration ten years ago, confirmed by allergist). The neurosurgical team asks whether aztreonam can be used as empiric gram-negative CNS coverage while awaiting culture results. Which of the following best characterizes the appropriateness of aztreonam in this specific clinical setting and explains the structural reason for its safety in a patient with IgE-mediated penicillin allergy?

• A) Aztreonam should be avoided in this patient because all beta-lactams share the same core beta-lactam ring that is recognized by IgE antibodies in penicillin-allergic patients; a non-beta-lactam agent such as a fluoroquinolone or aminoglycoside should replace any beta-lactam for gram-negative meningitis coverage in patients with confirmed penicillin anaphylaxis
• B) Aztreonam is appropriate for gram-negative CNS coverage and carries negligible penicillin cross-reactivity because it contains no beta-lactam ring; as the only monobactam class antibiotic in clinical use, aztreonam relies on a sulfonic acid-activated nitrogen mechanism rather than a beta-lactam carbonyl for PBP3 binding
• C) Aztreonam is appropriate empiric therapy and does not cross-react with penicillin; however, it covers gram-negative organisms including Pseudomonas aeruginosa as well as gram-positive cocci including Staphylococcus aureus and Enterococcus species that are common post-neurosurgical meningitis pathogens
• D) Aztreonam is contraindicated in post-neurosurgical meningitis because it does not penetrate the intact blood-brain barrier; in meningitis with disrupted blood-brain barrier it achieves only 5% of plasma concentrations in the CSF, which is below the MIC for most gram-negative post-neurosurgical pathogens
• E) Aztreonam is appropriate for gram-negative coverage in this patient with penicillin anaphylaxis because it is a monobactam — a monocyclic beta-lactam with a single unfused ring that lacks the bicyclic beta-lactam-thiazolidine structure of penicillins; the penicilloyl epitopes responsible for IgE sensitization are generated from the bicyclic penicillin degradation products and are structurally absent from aztreonam, producing negligible cross-reactivity; aztreonam's PBP3 selectivity provides coverage of aerobic gram-negative pathogens that are the dominant organisms in post-neurosurgical meningitis

6. [CASE 2 — QUESTION 2] Continuing with the same patient. CSF cultures return Pseudomonas aeruginosa susceptible to aztreonam, meropenem, and imipenem. The neurosurgery team notes the patient is improving on aztreonam but asks whether switching to a carbapenem would provide broader coverage and better CNS penetration. The infectious disease consultant acknowledges that if a carbapenem were to be used instead of aztreonam, meropenem would be strongly preferred over imipenem-cilastatin in this patient. Which of the following best explains the pharmacological basis for preferring meropenem over imipenem-cilastatin specifically in this post-neurosurgical patient with CNS infection?

• A) Meropenem has substantially broader Pseudomonas aeruginosa coverage than imipenem, achieving bactericidal killing against all Pseudomonas resistance phenotypes including MexAB-OprM efflux-overexpressing strains that imipenem cannot cover; for CNS Pseudomonas infections requiring comprehensive coverage, meropenem is always the superior agent
• B) Meropenem carries substantially lower seizure risk than imipenem-cilastatin because its C-1 beta-methyl group reduces interaction with GABA-A (gamma-aminobutyric acid type A) receptors at the picrotoxin-binding site; in a post-neurosurgical patient with direct CNS pathology, disrupted blood-brain barrier increasing CNS drug exposure, and the neuronal excitability inherent to meningeal infection, the lower seizurogenic potential of meropenem is particularly important
• C) Meropenem is preferred because cilastatin in imipenem-cilastatin competes with Pseudomonas aeruginosa outer membrane proteins for CNS uptake transporters, reducing the effective imipenem concentration at the site of meningeal infection; meropenem's single-agent formulation without cilastatin avoids this pharmacokinetic interference
• D) Meropenem is preferred over imipenem-cilastatin because imipenem does not achieve adequate CSF concentrations for Pseudomonas aeruginosa meningitis at any standard dose; meropenem's higher lipophilicity allows passive CNS penetration independent of blood-brain barrier disruption, making it pharmacokinetically superior for CNS infections
• E) Meropenem is preferred because this patient's penicillin allergy represents a contraindication to imipenem-cilastatin; imipenem's thiazolidine ring structure shares the bicyclic beta-lactam-thiazolidine epitopes with penicillin and would be expected to cause cross-reactive anaphylaxis, whereas meropenem's absence of a thiazolidine ring eliminates cross-reactivity risk in this penicillin-allergic patient

7. [CASE 2 — QUESTION 3] Continuing with the same patient. The patient continues on aztreonam for the confirmed Pseudomonas aeruginosa meningitis and improves clinically over the next 48 hours. A second set of CSF cultures drawn at 48 hours also grows methicillin-susceptible Staphylococcus aureus (MSSA). The neurosurgical team asks whether aztreonam can cover the newly identified MSSA co-pathogen without changing the regimen. Which of the following best explains why aztreonam cannot provide coverage for the MSSA co-infection and identifies what must be added?

• A) Aztreonam cannot cover MSSA because its spectrum is restricted to aerobic gram-negative bacilli; aztreonam's high-affinity PBP3 target is present in gram-negative organisms but gram-positive organisms including Staphylococcus aureus have different PBP configurations with negligible aztreonam affinity, and gram-positive bacteria lack the outer membrane required for aztreonam to reach any periplasmic target; an anti-staphylococcal agent — such as nafcillin, oxacillin, or cefazolin for MSSA — must be added to the regimen
• B) Aztreonam cannot cover MSSA because it is inactivated by the penicillinase produced by most MSSA strains; since MSSA's penicillinase efficiently hydrolyzes the monocyclic aztreonam ring, anti-staphylococcal beta-lactamase-stable penicillins (nafcillin, oxacillin) are the only options; cephalosporins are also inactivated by MSSA penicillinase and cannot substitute
• C) Aztreonam covers MSSA at standard doses because the aztreonam concentration in CSF with inflamed meninges exceeds the MSSA PBP2 binding threshold; however, the clinical team should confirm MSSA susceptibility by requesting specific aztreonam MIC testing against the CSF isolate, as routine susceptibility panels do not include aztreonam for gram-positive cocci
• D) Aztreonam cannot cover MSSA because the post-neurosurgical blood-brain barrier disruption allows intracranial macrophages to inactivate aztreonam through oxidative burst metabolism before it can reach the gram-positive meningeal focus; a lipophilic CNS-penetrating anti-staphylococcal agent such as linezolid must replace aztreonam entirely
• E) Aztreonam cannot cover MSSA, but this is due to the patient's penicillin allergy creating immunological cross-reactivity that prevents any beta-lactam — including aztreonam — from being used against gram-positive organisms; vancomycin must be used as the sole anti-staphylococcal agent because it is the only gram-positive agent not subject to penicillin cross-reactivity restrictions

8. [CASE 2 — QUESTION 4] Continuing with the same patient. Anti-staphylococcal coverage is added and the patient continues to improve. A pharmacy resident reviewing the case notes that aztreonam was used safely in a patient with penicillin anaphylaxis, and asks whether there are any other beta-lactam antibiotics with which aztreonam does share cross-reactivity risk — distinct from the well-established safety with penicillins. Which of the following correctly identifies the specific cross-reactivity concern for aztreonam that is separate from penicillin allergy?

• A) Aztreonam shares cross-reactivity risk with carbapenems (imipenem and meropenem) because all three drug classes share the same pyroline ring substituent at C-1 of the bicyclic ring; patients with aztreonam allergy have a 40% probability of carbapenem cross-reactivity that must be assessed before carbapenem therapy
• B) Aztreonam shares cross-reactivity risk with ampicillin and amoxicillin specifically among the penicillins because aztreonam's R1 side chain is identical to the aminobenzyl R1 side chain of aminopenicillins; patients tolerant of other penicillins may still react to aztreonam if they are specifically sensitized to the aminobenzyl epitope
• C) Aztreonam has no cross-reactivity with any other beta-lactam class because its unique monocyclic structure means that all beta-lactam degradation epitopes are structurally absent; the absence of any fused ring structure makes aztreonam immunologically isolated from all other beta-lactam classes
• D) Aztreonam shares an identical R1 aminothiazole side chain with ceftazidime, a third-generation cephalosporin; patients specifically sensitized to ceftazidime's R1 side chain may exhibit cross-reactivity to aztreonam, and conversely, aztreonam-allergic patients may react to ceftazidime; this is a distinct cross-reactivity concern from penicillin allergy and is clinically relevant when ceftazidime is being considered in an aztreonam-allergic patient
• E) Aztreonam shares cross-reactivity risk with cefepime and cefpirome (fourth-generation cephalosporins) because these drugs share aztreonam's sulfonic acid moiety on the beta-lactam nitrogen; IgE antibodies directed against the sulfonic acid-nitrogen hapten of aztreonam cross-react with the same hapten expressed by fourth-generation cephalosporins

9. [CASE 3 — QUESTION 1] A 55-year-old woman with a renal transplant on tacrolimus and mycophenolate is admitted with urosepsis. Urine and blood cultures grow Klebsiella pneumoniae. Carbapenemase PCR returns positive for NDM (New Delhi metallo-beta-lactamase). Susceptibility testing confirms resistance to all carbapenems, ceftazidime-avibactam, and meropenem-vaborbactam. The isolate is also confirmed to co-produce a CTX-M-15 ESBL (extended-spectrum beta-lactamase) on the same resistance plasmid. Aztreonam-avibactam is the only remaining active regimen. The infectious disease team explains the pharmacological rationale to the transplant team. Which of the following best explains why each of the failed agents is pharmacologically inactive against this isolate while aztreonam-avibactam retains activity?

• A) All carbapenems fail because NDM has acquired resistance to all carbapenem-range PBP targets through horizontal gene transfer of modified PBP2 genes; ceftazidime-avibactam and meropenem-vaborbactam fail because their inhibitors are hydrolyzed by CTX-M-15 before they can accumulate; aztreonam-avibactam succeeds because aztreonam's sulfonic acid group prevents CTX-M-15 hydrolysis while avibactam independently inhibits NDM
• B) All carbapenems fail because NDM is a class B zinc-dependent metallo-beta-lactamase that hydrolyzes the beta-lactam ring of all carbapenems; ceftazidime-avibactam fails because avibactam cannot inhibit NDM (no catalytic serine) and ceftazidime is hydrolyzed by NDM; meropenem-vaborbactam fails for the same reason — vaborbactam cannot inhibit NDM; aztreonam-avibactam succeeds because aztreonam is intrinsically NDM-stable (its monocyclic ring resists zinc-dependent hydrolysis) while avibactam inhibits the co-produced CTX-M-15 ESBL that would otherwise destroy aztreonam
• C) All carbapenems fail because NDM produces a poreless outer membrane phenotype in Klebsiella that prevents all beta-lactams from entering the periplasm; ceftazidime-avibactam and meropenem-vaborbactam fail because neither combination uses TonB-dependent uptake; aztreonam-avibactam succeeds because aztreonam is conjugated to a siderophore moiety that uses TonB-dependent transporters to bypass the poreless outer membrane
• D) All carbapenems fail because NDM upregulates the AcrAB-TolC efflux pump to export all beta-lactam antibiotics before they engage PBP targets; ceftazidime-avibactam fails because avibactam inhibits AcrAB-TolC only partially, and ceftazidime is expelled before adequate periplasmic concentrations are reached; aztreonam-avibactam succeeds because aztreonam's monocyclic structure is not a substrate for AcrAB-TolC
• E) All carbapenems fail because NDM's zinc-dependent hydrolysis generates a pro-inflammatory lipid A fragment that neutralizes carbapenem antibacterial activity by binding to carbapenem molecules in the bloodstream; ceftazidime-avibactam and meropenem-vaborbactam fail for the same reason; aztreonam-avibactam succeeds because aztreonam's sulfonic acid group prevents lipid A fragment binding

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Aztreonam-avibactam is initiated. The transplant pharmacist raises a question about potential drug-drug interactions between aztreonam-avibactam and the patient's tacrolimus immunosuppression. Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index that is extensively metabolized by CYP3A4 (cytochrome P450 3A4) and P-glycoprotein (P-gp). Which of the following best describes the pharmacokinetic interaction risk between aztreonam-avibactam and tacrolimus in this patient?

• A) Aztreonam is a potent CYP3A4 inducer that substantially reduces tacrolimus blood concentrations; aztreonam-avibactam must be used with a prophylactic 50% tacrolimus dose increase at initiation and careful daily tacrolimus level monitoring throughout therapy
• B) Avibactam is a P-glycoprotein inhibitor that reduces tacrolimus efflux from intestinal enterocytes, dramatically increasing tacrolimus oral bioavailability and creating a risk of tacrolimus toxicity (nephrotoxicity, neurotoxicity) during aztreonam-avibactam therapy; tacrolimus levels must be reduced by approximately 50% at initiation
• C) Aztreonam is metabolized by CYP3A4 to an active metabolite that competes with tacrolimus for CYP3A4 binding, reducing tacrolimus metabolism and increasing tacrolimus blood levels; avibactam has no CYP3A4 activity but its renal elimination pathway competes with tacrolimus for organic anion transporter (OAT1) secretion in the proximal tubule
• D) Aztreonam and avibactam are not significantly metabolized by cytochrome P450 enzymes and are not P-glycoprotein substrates or inhibitors; aztreonam-avibactam is not expected to produce a pharmacokinetic drug-drug interaction with tacrolimus through CYP3A4 or P-gp pathways; however, tacrolimus levels should still be monitored closely because critical illness and the inflammatory response to severe infection alter CYP3A4 activity and tacrolimus pharmacokinetics independently of any direct drug interaction
• E) Avibactam inhibits CYP3A4 through a mechanism-based irreversible inactivation similar to macrolide antibiotics; this inhibition reduces tacrolimus metabolism, increases tacrolimus blood concentrations by 3- to 5-fold, and requires an immediate empiric tacrolimus dose reduction of 70% at the initiation of aztreonam-avibactam therapy

11. [CASE 3 — QUESTION 3] Continuing with the same patient. A microbiology resident reviewing the case notes that the automated susceptibility panel reported aztreonam as "susceptible" for this isolate as monotherapy, despite the isolate co-producing a CTX-M-15 ESBL that can hydrolyze aztreonam. The resident asks why avibactam is still essential if the isolate is susceptible to aztreonam alone by standard testing. Which of the following best explains why the aztreonam monotherapy susceptibility result does not predict clinical success and why avibactam is essential despite the susceptibility report?

• A) The aztreonam susceptibility result is a laboratory error caused by the acidic pH of the automated susceptibility system inhibiting CTX-M-15 enzyme activity in vitro; avibactam is essential because at physiological pH in the patient's bloodstream, CTX-M-15 regains full activity and hydrolyzes aztreonam before it can reach therapeutic concentrations
• B) The aztreonam susceptibility result reflects testing at standard laboratory incubation temperature of 35°C; at human body temperature of 37°C, CTX-M-15 enzyme kinetics increase 4-fold, hydrolyzing aztreonam faster than it can accumulate; avibactam is essential to suppress the temperature-enhanced CTX-M-15 activity in the patient
• C) Automated susceptibility testing uses a standardized low bacterial inoculum; at low inocula, the CTX-M-15 ESBL enzyme produced by the bacteria may be insufficient to hydrolyze aztreonam before it reaches its PBP3 target, producing a susceptible MIC; however, in vivo infections involve far higher bacterial burdens at the site of infection, generating sufficient CTX-M-15 enzyme to overwhelm aztreonam at achievable clinical concentrations — the inoculum effect; avibactam inhibits CTX-M-15, eliminating this inoculum effect and ensuring reliable aztreonam activity regardless of bacterial burden
• D) The aztreonam susceptibility result is accurate for the free drug concentration achieved with standard IV dosing; avibactam is still essential because without it, aztreonam is metabolized by hepatic CYP2C9 to an inactive sulfoxide metabolite before reaching the site of infection; avibactam inhibits CYP2C9 and preserves the aztreonam parent compound
• E) Aztreonam susceptibility results for NDM-producing organisms are systematically unreliable because automated susceptibility systems cannot distinguish organisms that produce NDM alone from those that co-produce NDM with ESBL; the result should be disregarded for any NDM-positive isolate, and empiric therapy for all NDM-CRE should use aztreonam-avibactam without reference to susceptibility testing results

12. [CASE 3 — QUESTION 4] Continuing with the same patient. The patient responds to aztreonam-avibactam with defervescence by day 3 and sterilization of repeat blood cultures by day 5. The team begins planning treatment duration and transition. The transplant team asks whether any modification of the aztreonam-avibactam dose is required given the patient's baseline renal function, which has returned to her transplant baseline of CrCl 38 mL/min. They also ask what additional management step is most critical to ensure treatment success beyond antibiotic therapy alone. Which of the following best addresses both questions?

• A) Aztreonam and avibactam are both primarily renally eliminated; at CrCl 38 mL/min, dose adjustment of both components is required compared to the standard regimen designed for normal renal function; additionally, urological source control — assessment and management of the urinary tract focus (such as evaluation for obstructive uropathy, abscess, or retained foreign material in the transplant urinary anatomy) — is the most critical non-antibiotic management step, as bacteremia from a urinary source will recur without elimination of the anatomical focus
• B) No dose adjustment is required for aztreonam-avibactam at CrCl 38 mL/min because aztreonam is not renally eliminated; it is hepatically conjugated to glucuronide and does not accumulate in mild renal impairment; the most critical additional management step is escalating tacrolimus to prevent rejection flare during the inflammatory response to bacteremia
• C) Aztreonam requires dose reduction at CrCl 38 mL/min but avibactam is entirely hepatically cleared and requires no adjustment; the most critical additional management step is adding an aminoglycoside for synergy because aztreonam-avibactam monotherapy has not demonstrated bactericidal activity against NDM-CRE in clinical outcome studies and requires a second active agent for cure
• D) No dose adjustment is required at CrCl 38 mL/min because this creatinine clearance is above the threshold for carbapenem dose modification; the most critical additional management step is repeat carbapenemase PCR testing at day 7 to confirm that on-therapy resistance has not emerged, as NDM-CRE is more prone to acquiring new carbapenemase genes during therapy than KPC-CRE
• E) Aztreonam-avibactam requires dose reduction only when CrCl falls below 10 mL/min; at CrCl 38 mL/min standard dosing is appropriate; the most critical non-antibiotic management step is therapeutic drug monitoring of aztreonam trough levels to confirm adequate time above MIC throughout the dosing interval, as NDM-producing organisms typically have aztreonam MICs near the susceptibility breakpoint

13. [CASE 4 — QUESTION 1] A 28-year-old man with cystic fibrosis (CF) has been managed with inhaled aztreonam lysine for inhalation (AZLI) for chronic Pseudomonas aeruginosa airway colonization for two years. His FEV1 (forced expiratory volume in 1 second) has been stable on this regimen. His pulmonologist explains to a third-year medical student rotating through the CF clinic why aztreonam is chosen as an inhaled antibiotic for chronic Pseudomonas suppression in CF. The student asks specifically what makes aztreonam appropriate for this indication in terms of its spectrum and mechanism of action. Which of the following best answers the student's question?

• A) Aztreonam is chosen for CF Pseudomonas suppression because it is the only available antibiotic that directly disrupts Pseudomonas aeruginosa biofilm exopolysaccharide production; its monocyclic ring structure intercalates into alginate polymer chains in the biofilm matrix, physically disrupting the protective biofilm before reaching bacterial PBP targets
• B) Aztreonam is chosen because it is the only beta-lactam with meaningful post-antibiotic effect (PAE) against Pseudomonas aeruginosa; its PAE of greater than 8 hours allows once-daily inhalation dosing with sustained bacteriostatic suppression throughout the 24-hour interval without requiring continuous airway drug exposure
• C) Aztreonam is chosen because it achieves the highest intracellular macrophage concentrations of any beta-lactam antibiotic after inhalation; Pseudomonas aeruginosa in CF airways lives primarily within alveolar macrophages, and aztreonam's macrophage penetration allows it to reach the intracellular bacterial niche that tobramycin cannot access
• D) Aztreonam is appropriate for CF Pseudomonas suppression because its spectrum is restricted to aerobic gram-negative bacilli including Pseudomonas aeruginosa through high-affinity PBP3 binding, providing targeted anti-Pseudomonas activity without disrupting the gram-positive components of the CF airway microbiome; delivered by inhalation, it achieves high local airway concentrations directly at the site of colonization while limiting systemic exposure
• E) Aztreonam is chosen over tobramycin for all CF patients because beta-lactam antibiotics have inherently superior activity against Pseudomonas aeruginosa biofilms compared to aminoglycosides; tobramycin's positive charge causes it to bind to biofilm matrix anionic polymers before reaching bacteria, while aztreonam's neutral charge allows unrestricted biofilm penetration

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Three months later, the patient develops a pulmonary exacerbation with increased sputum production, worsening dyspnea, and a 9% decline in FEV1 from his stable baseline. Sputum culture grows Pseudomonas aeruginosa susceptible to meropenem and aztreonam. His pulmonologist admits him for IV antibiotic therapy. A medical student asks why the patient needs intravenous antibiotics when he is already receiving AZLI — an aztreonam-based regimen — for chronic suppression. Which of the following best explains the limitation of AZLI for treatment of an acute CF pulmonary exacerbation and identifies the appropriate therapeutic approach?

• A) AZLI becomes ineffective during pulmonary exacerbations because increased airway mucus viscosity in the exacerbated CF lung prevents nebulized aztreonam from penetrating to the distal airways where Pseudomonas colonization is densest; intravenous aztreonam achieves more uniform lung distribution by reaching all airway zones via the systemic circulation
• B) AZLI must be discontinued during acute exacerbations because it causes bronchospasm at the higher doses required for treatment; standard doses used for chronic suppression are safe, but doubling the dose for acute treatment produces a 60% rate of severe bronchospasm in CF patients; IV antibiotics are required to achieve adequate doses without airway irritation
• C) AZLI is an inhaled suppressive antibiotic used for maintenance reduction of Pseudomonas burden in stable CF; it is not approved or established as adequate treatment for acute pulmonary exacerbations, which require systemic antibiotic concentrations achievable only with intravenous therapy to treat the deeper parenchymal infection and the systemic inflammatory response; IV antipseudomonal therapy — typically an antipseudomonal beta-lactam such as meropenem plus an inhaled aminoglycoside or IV aminoglycoside — is the standard approach for CF acute exacerbations
• D) AZLI cannot treat the acute exacerbation because aztreonam is not active against the mucoid Pseudomonas aeruginosa phenotype that predominates during exacerbations; mucoid Pseudomonas overproduces alginate, which chelates aztreonam's sulfonic acid group and inactivates the drug; non-mucoid Pseudomonas (present during chronic stable colonization) is susceptible
• E) AZLI must be replaced with intravenous aztreonam during acute exacerbations to achieve the same PBP3 inhibitory mechanism systemically; the inhaled and IV formulations of aztreonam are pharmacologically identical but the IV route is required to treat the bacteremic component of CF exacerbations, which AZLI cannot reach through inhaled delivery

15. [CASE 4 — QUESTION 3] Continuing with the same patient. IV meropenem is initiated for the CF pulmonary exacerbation. The clinical pharmacist recommends administering meropenem as a 3-hour extended infusion rather than the standard 30-minute infusion, noting that the Pseudomonas aeruginosa isolate has an elevated meropenem MIC (minimum inhibitory concentration) that is near the susceptibility breakpoint. The student asks why extending the infusion time improves activity against a borderline-susceptible Pseudomonas when the total daily dose of meropenem remains the same. Which of the following best explains the pharmacodynamic rationale for extended-infusion meropenem in this context?

• A) Extended infusion is preferred because it produces a higher peak meropenem concentration (Cmax) in pulmonary epithelial lining fluid (ELF); Pseudomonas aeruginosa in CF airways is killed through concentration-dependent pharmacodynamics, and achieving a Cmax/MIC ratio above 10 in ELF is the pharmacodynamic target that standard 30-minute infusion cannot achieve against a near-breakpoint MIC isolate
• B) Meropenem, like all beta-lactam antibiotics, exhibits time-dependent bactericidal pharmacodynamics — efficacy is determined by the proportion of the dosing interval during which free drug concentration exceeds the MIC; extending the infusion from 30 minutes to 3 hours prolongs the period of drug delivery, increasing the percentage of the dosing interval during which plasma and tissue drug concentrations remain above the near-breakpoint MIC and optimizing the pharmacodynamic target of time above MIC
• C) Extended infusion is used because meropenem undergoes spontaneous ring hydrolysis to inactive product at body temperature; a 30-minute rapid infusion delivers intact drug too quickly for the unstable meropenem molecule to remain active in the systemic circulation; the 3-hour extended infusion allows continuous replacement of degraded meropenem, maintaining the effective meropenem concentration without increasing total dose
• D) Extended infusion optimizes meropenem activity through a post-antibiotic effect (PAE) mechanism; meropenem's PAE against Pseudomonas aeruginosa is triggered only when drug is delivered slowly over more than 2 hours; rapid 30-minute infusion does not engage the PAE signaling pathway and produces only 30 minutes of bacterial suppression, whereas extended infusion activates the PAE and produces 6–8 hours of post-infusion bacterial suppression
• E) Extended infusion is preferred for this CF patient because meropenem's volume of distribution in CF patients is dramatically higher than in non-CF patients due to increased total body water from mucus hypersecretion; the 3-hour infusion allows equilibration to the expanded CF distribution volume, achieving therapeutic lung tissue concentrations that standard rapid infusion cannot reach

16. [CASE 4 — QUESTION 4] Continuing with the same patient. The patient completes a 14-day course of IV meropenem with clinical improvement and FEV1 recovery to near-baseline. The pulmonologist plans to resume AZLI for chronic Pseudomonas suppression after discharge. The patient asks why inhaled antibiotic therapy is continued long-term when his Pseudomonas is apparently suppressed after IV treatment. The pulmonologist also mentions that the post-treatment sputum Pseudomonas isolate should be susceptibility-tested before resuming AZLI. Which of the following best explains the rationale for continuing long-term inhaled suppressive therapy after IV treatment and the reason for repeat susceptibility testing?

• A) Inhaled suppressive therapy is continued because IV meropenem achieves complete eradication of Pseudomonas aeruginosa from the CF airway during a 14-day course; AZLI is resumed to prevent re-colonization from environmental Pseudomonas sources, not to suppress persistent airway organisms; susceptibility testing is needed to confirm that the new environmental Pseudomonas strain is aztreonam-susceptible before re-establishing prophylaxis
• B) AZLI is continued indefinitely because Pseudomonas aeruginosa cannot be eradicated from CF airways once chronic colonization is established; IV antibiotic courses suppress bacterial burden and reduce inflammation but do not achieve microbiological cure; without ongoing inhaled suppression, Pseudomonas burden will rebound, producing another exacerbation; repeat susceptibility testing is important because on-therapy resistance mutations may have emerged during the IV meropenem course that could affect aztreonam susceptibility
• C) AZLI is continued because aztreonam's monocyclic ring structure prevents Pseudomonas aeruginosa from developing resistance through standard beta-lactamase induction; since resistance cannot develop to AZLI, it is the preferred long-term agent; susceptibility testing is requested only as a regulatory requirement for insurance reimbursement documentation
• D) AZLI is resumed because inhaled aztreonam achieves superior eradication rates compared to IV meropenem for CF Pseudomonas in randomized trials; the IV course was used only because of acute severity, but AZLI is the pharmacologically superior agent; susceptibility testing is needed to confirm that the IV course did not select for meropenem-resistant variants that would contaminate future IV therapy choices
• E) Chronic suppressive inhaled antibiotic therapy is indicated in CF with established Pseudomonas colonization because it reduces exacerbation frequency, preserves lung function over time, and improves quality of life; Pseudomonas aeruginosa is not eradicated by IV courses in chronically colonized CF patients and will rebound without suppression; repeat susceptibility testing after an IV course is clinically important because antibiotic-selective pressure during the IV course — particularly from meropenem — can select for resistance mutations including AmpC derepression, OprD loss, and efflux pump upregulation that may affect not only meropenem susceptibility but potentially cross-resistance patterns relevant to aztreonam

17. [CASE 5 — QUESTION 1] A 78-year-old woman with CKD stage 3b (CrCl 32 mL/min), hypertension, and type 2 diabetes presents with fever and bacteremia. Blood cultures grow Escherichia coli producing a CTX-M-15 ESBL, susceptible to ertapenem with a low MIC. She is hemodynamically stable after 48 hours of IV therapy. The infectious disease team plans to discharge her on OPAT. They select ertapenem 1 g IV once daily as the OPAT agent. A pharmacy student asks what pharmacokinetic properties make ertapenem uniquely suitable for once-daily OPAT dosing in this patient with reduced renal function. Which of the following best identifies the relevant pharmacokinetic properties and confirms ertapenem's appropriateness?

• A) Ertapenem's approximately 95% plasma protein binding produces an extended serum half-life of approximately 4 hours by limiting the free drug fraction available for glomerular filtration and reducing renal clearance rate; this extended half-life sustains free drug concentrations above the MIC of ESBL-producing E. coli throughout the 24-hour dosing interval; as CrCl declines in patients like this woman, ertapenem's half-life extends further, providing enhanced time above MIC that makes once-daily dosing even more reliable in mild-to-moderate renal impairment
• B) Ertapenem's once-daily dosing is justified by its concentration-dependent pharmacodynamics; the high peak concentration achieved after a 1 g bolus dose produces a Cmax/MIC ratio greater than 10 against ESBL-producing E. coli, achieving the pharmacodynamic target with a single daily dose independent of drug half-life
• C) Ertapenem is suitable for OPAT because it is available as an oral prodrug that can be dispensed to the patient for home self-administration, eliminating the need for home nursing visits; the oral ertapenem formulation achieves bioavailability of approximately 60%, producing plasma concentrations equivalent to IV dosing for ESBL-E infections
• D) Ertapenem's once-daily OPAT dosing is possible because it undergoes extensive enterohepatic recirculation after biliary secretion; the drug is re-absorbed from the intestine throughout the 24-hour period, creating a sustained-release profile that maintains plasma concentrations above the MIC without the need for frequent intravenous infusions
• E) Ertapenem is specifically preferred over meropenem for OPAT in patients with reduced renal function because ertapenem is exclusively hepatically eliminated; in patients with CrCl below 50 mL/min, meropenem accumulates to toxic concentrations while ertapenem's hepatic clearance remains unaffected by renal impairment, making ertapenem safer in this patient

18. [CASE 5 — QUESTION 2] Continuing with the same patient. She is discharged on ertapenem OPAT and doing well for the first three days. On day 4 she develops new-onset dyspnea and productive cough. Her daughter brings her to the emergency department. Chest X-ray shows a new left lower lobe infiltrate. Sputum Gram stain shows gram-negative rods. She is admitted. Her home nurse reports she has been receiving all ertapenem doses as scheduled. The most likely explanation for this new respiratory illness is sought. Which of the following best identifies the pharmacological explanation for why ertapenem OPAT did not prevent this new pulmonary infection?

• A) Ertapenem's extended half-life in patients with CKD causes drug accumulation over 4 days to concentrations that paradoxically suppress the patient's immune response through GABA-A receptor-mediated reduction in neutrophil chemotaxis, creating an immunocompromised state that allowed a Pseudomonas pneumonia to establish
• B) The new Pseudomonas pneumonia developed because ertapenem's high protein binding reduces free drug lung tissue concentrations below the MIC for all gram-negative pneumonia pathogens; protein-bound drug cannot cross the pulmonary capillary endothelium, making ertapenem pharmacokinetically inappropriate for any pulmonary infection regardless of susceptibility
• C) Ertapenem selects for Pseudomonas aeruginosa overgrowth by eliminating competing Enterobacteriaceae from the respiratory flora; the ESBL E. coli bacteremia was effectively treated, but clearing E. coli from the airway created an ecological niche that Pseudomonas colonized; this is an expected consequence of broad-spectrum carbapenem therapy
• D) The new pulmonary infection occurred because ertapenem was not dosed with appropriate extended infusion for OPAT; standard 30-minute infusion produces inadequate time above MIC for any gram-negative pulmonary pathogen including Pseudomonas, and only 3-hour extended infusion would have achieved the pharmacodynamic target needed to prevent pneumonia
• E) Ertapenem lacks reliable activity against Pseudomonas aeruginosa; the new pneumonia is most likely a Pseudomonas lower respiratory tract infection that ertapenem provided no coverage against regardless of dosing or duration; ertapenem must be replaced with an antipseudomonal agent — an antipseudomonal carbapenem (meropenem), an antipseudomonal beta-lactam/inhibitor, or another agent with confirmed Pseudomonas activity based on susceptibility testing

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The sputum and new blood cultures grow Pseudomonas aeruginosa susceptible to meropenem and imipenem. The team needs to select an antipseudomonal carbapenem. An intern proposes imipenem-cilastatin since it is available on the formulary. The attending physician recommends meropenem instead, citing two independent pharmacological reasons specific to this patient. Which of the following best identifies both reasons for preferring meropenem over imipenem-cilastatin in this 78-year-old woman with CKD stage 3b?

• A) Meropenem is preferred because it does not require cilastatin co-administration, reducing the pill burden for a patient on multiple medications; and meropenem achieves higher bronchoalveolar lavage (BAL) concentrations than imipenem due to lower protein binding, making it pharmacokinetically superior for pulmonary Pseudomonas infections
• B) Meropenem is preferred because it has broader anti-Pseudomonas coverage than imipenem, including activity against MexAB-OprM efflux-overexpressing strains; and meropenem does not require renal dose adjustment at any degree of renal impairment because it undergoes DHP-I-independent renal metabolism that is unaffected by reduced glomerular filtration
• C) Meropenem is preferred because this patient's prior ertapenem exposure selected for ertapenem-specific carbapenem resistance; imipenem would show cross-resistance to ertapenem-selected resistance mechanisms while meropenem's different C-2 side chain overcomes this cross-resistance; additionally meropenem has no seizure risk because it is renally cleared before reaching the blood-brain barrier
• D) Meropenem is preferred over imipenem-cilastatin for two independent pharmacological reasons: first, imipenem's GABA-A (gamma-aminobutyric acid type A) receptor antagonism at the picrotoxin-binding site carries significant seizure risk that is amplified in this 78-year-old patient by her CKD-related reduced drug clearance and the neuronal stress of acute illness; meropenem's C-1 beta-methyl group substantially reduces this seizurogenic potential; second, meropenem does not require cilastatin, and cilastatin is renally cleared — at CrCl 32 mL/min cilastatin accumulation over a prolonged treatment course could independently alter renal tubular DHP-I inhibition pharmacokinetics in unpredictable ways
• E) Meropenem is preferred because imipenem-cilastatin is absolutely contraindicated in patients with CrCl below 40 mL/min due to FDA black-box warnings for nephrotoxicity from imipenem's DHP-I metabolites in reduced renal function; meropenem has no such contraindication and can be used at standard doses in any degree of renal impairment without dose adjustment

20. [CASE 5 — QUESTION 4] Continuing with the same patient. Meropenem is selected and the team discusses optimal dosing for this patient's CrCl of 32 mL/min. The clinical pharmacist notes that standard meropenem dosing is 1 g IV every 8 hours for normal renal function, but dose adjustment is required here. The pharmacist also proposes using extended infusion (3-hour infusion of each dose) for the near-breakpoint Pseudomonas MIC. The intern asks whether reducing the dose for renal impairment while simultaneously using extended infusion to optimize pharmacodynamics creates a contradiction — if the dose is lower, will extended infusion still achieve adequate time above MIC? Which of the following best resolves this apparent contradiction and explains how both dose reduction and extended infusion can be simultaneously appropriate?

• A) The apparent contradiction is real; dose reduction and extended infusion cannot be simultaneously appropriate because a lower dose produces a lower peak concentration that falls below the MIC faster than the standard dose; in patients with renal impairment the dose should not be reduced but the interval should be extended to maintain standard peak concentrations while reducing accumulation between doses
• B) The contradiction is resolved by eliminating extended infusion in renally impaired patients; renal impairment itself extends the effective meropenem half-life sufficiently to sustain adequate time above MIC without any infusion technique modification; extended infusion is reserved for patients with normal renal function where rapid clearance creates the primary pharmacodynamic challenge
• C) Dose reduction for renal impairment addresses toxicity risk from drug accumulation between doses — reducing the total drug delivered per interval to prevent excessive trough concentrations; extended infusion addresses the pharmacodynamic requirement of sustaining free drug concentration above the MIC during each dose's contribution to the dosing interval; these are independent pharmacokinetic and pharmacodynamic optimizations that can be combined — a lower renal-adjusted dose delivered over 3 hours maintains adequate time above MIC while avoiding accumulation to toxic levels
• D) The contradiction is resolved by switching to once-daily meropenem dosing in renally impaired patients; the extended half-life from reduced renal clearance converts meropenem from a time-dependent to a concentration-dependent drug, making once-daily extended infusion the optimal strategy; this mimics the ertapenem pharmacokinetic profile that the patient was on previously
• E) Dose reduction is unnecessary in this patient because CrCl of 32 mL/min is above the standard meropenem renal dose adjustment threshold of 26 mL/min; the full standard dose of 1 g every 8 hours should be maintained, and extended infusion alone is sufficient to optimize pharmacodynamics without any dose modification

21. [CASE 6 — QUESTION 1] A 60-year-old man is in the surgical ICU following a motor vehicle accident with polytrauma and bowel injury. On hospital day 9 he develops ventilator-associated pneumonia. BAL cultures grow carbapenem-resistant Acinetobacter baumannii (CRAB) producing OXA-23. The isolate is resistant to imipenem, meropenem, ceftazidime-avibactam, meropenem-vaborbactam, and tobramycin. Susceptibility testing shows the isolate is susceptible to sulbactam-durlobactam (Xacduro). The ICU team asks why this combination retains activity when all other beta-lactam combinations have failed. Which of the following best explains the pharmacological basis for sulbactam-durlobactam's activity against this OXA-23-producing CRAB isolate?

• A) Sulbactam-durlobactam retains activity because durlobactam is a siderophore-conjugated inhibitor that uses TonB-dependent iron-uptake transporters to cross the outer membrane of CRAB; once inside the periplasm, durlobactam inhibits OXA-23 while sulbactam binds PBP targets; this combined delivery and inhibition mechanism bypasses the porin loss that causes resistance to standard carbapenems and cephalosporin-based combinations
• B) Sulbactam retains activity against Acinetobacter baumannii because it has direct intrinsic antibacterial activity through high-affinity binding to PBP1 and PBP3 — a property unique among beta-lactamase inhibitors; OXA-23 (a class D serine carbapenemase) hydrolyzes sulbactam in CRAB strains, inactivating it; durlobactam is a DBO (diazabicyclooctane) inhibitor that inhibits OXA-23 by forming a reversible covalent carbamylation with its catalytic serine, protecting sulbactam from hydrolysis and restoring its PBP-mediated bactericidal activity against CRAB
• C) Sulbactam-durlobactam retains activity because durlobactam chelates the zinc cofactors of OXA-23, converting it from an active zinc-dependent carbapenemase to an inactive apo-enzyme; sulbactam then accumulates in the periplasm without enzymatic hydrolysis and binds both PBP1 and PBP3; this zinc chelation mechanism is selective for OXA-type enzymes and does not affect KPC or NDM
• D) Sulbactam-durlobactam retains activity because cefoperazone — the beta-lactam partner for sulbactam in the cefoperazone-sulbactam combination — has intrinsic anti-Acinetobacter activity that carbapenems lack; durlobactam protects cefoperazone from OXA-23 hydrolysis; when used as Xacduro, the cefoperazone provides the antibacterial activity while sulbactam-durlobactam provides dual enzyme protection
• E) Sulbactam-durlobactam retains activity because both sulbactam and durlobactam penetrate the CRAB outer membrane via passive lipid bilayer diffusion that is unaffected by porin loss; once in the periplasm, sulbactam inhibits OXA-23 through a suicide inhibitor reaction while durlobactam provides the direct antibacterial PBP binding activity against Acinetobacter PBP3

22. [CASE 6 — QUESTION 2] Continuing with the same patient. Before selecting sulbactam-durlobactam, the ICU pharmacist had reviewed both sulbactam-durlobactam and cefiderocol as options, noting that the CRAB isolate was also susceptible to cefiderocol. The infectious disease consultant specifically preferred sulbactam-durlobactam over cefiderocol as first-line therapy. The ICU fellow asks what clinical evidence drove this preference. Which of the following best describes the evidence basis for preferring sulbactam-durlobactam over cefiderocol as first-line monotherapy for this CRAB pneumonia?

• A) The CREDIBLE-CR trial (a non-randomized, open-label, pathogen-focused descriptive phase 3 trial comparing cefiderocol to best available therapy for carbapenem-resistant gram-negative infections) reported numerically higher all-cause mortality in the cefiderocol arm specifically in the Acinetobacter baumannii patient subset compared to best available therapy; this unexpected mortality signal — not yet mechanistically explained — argues for preferring sulbactam-durlobactam, the first FDA-approved targeted therapy specifically indicated for CRAB infections, as first-line monotherapy when it is available and the isolate is susceptible
• B) The CREDIBLE-CR trial demonstrated that cefiderocol was uniformly inferior to sulbactam-durlobactam across all carbapenem-resistant pathogens in a head-to-head randomized trial; sulbactam-durlobactam achieved superior 28-day clinical cure rates for CRAB in this direct comparison, establishing it as the evidence-based standard of care in all guidelines
• C) Cefiderocol is preferred over sulbactam-durlobactam by all current IDSA (Infectious Diseases Society of America) guidelines for CRAB infections based on in vitro potency data; the consultant's preference for sulbactam-durlobactam represents an off-guideline decision that should be discussed with the patient's family
• D) Sulbactam-durlobactam is preferred because cefiderocol requires an intact immune system to achieve bactericidal killing against CRAB; in immunocompromised or critically ill patients, cefiderocol's siderophore mechanism is impaired by the suppression of TonB-dependent transporter expression that occurs during systemic inflammatory response syndrome
• E) Sulbactam-durlobactam is preferred because cefiderocol causes significant nephrotoxicity specifically in CRAB-infected patients through a mechanism involving OXA-23-mediated conversion of cefiderocol to a nephrotoxic periplasmic fragment; this adverse effect was identified in the CREDIBLE-CR trial and is the primary reason cefiderocol is avoided for CRAB when alternatives exist

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Sulbactam-durlobactam is initiated and the patient improves clinically. A pharmacy resident on rotation asks the consultant to clarify the spectrum of sulbactam-durlobactam compared to the other novel CRE combinations: does sulbactam-durlobactam work against KPC-CRE, NDM-CRE, or OXA-48-CRE in addition to CRAB? Which of the following correctly characterizes the clinical spectrum of sulbactam-durlobactam relative to other novel combinations?

• A) Sulbactam-durlobactam has the broadest spectrum of all novel beta-lactam combinations; it covers KPC-CRE, NDM-CRE, OXA-48-CRE, and CRAB because durlobactam inhibits all four Ambler beta-lactamase classes including class B metallo-beta-lactamases; the FDA approved it specifically for CRAB only due to the CRAB data in clinical trials, but off-label use is supported for all CRE genotypes
• B) Sulbactam-durlobactam covers CRAB and NDM-CRE but not KPC-CRE or OXA-48-CRE; sulbactam's PBP1/PBP3 antibacterial activity is specific to organisms with Acinetobacter-type outer membrane architecture, and NDM-producing organisms share this architecture; KPC and OXA-48 producers have different outer membrane porins that prevent sulbactam from accessing its PBP targets
• C) Sulbactam-durlobactam is equivalent to ceftazidime-avibactam in spectrum; durlobactam and avibactam are both DBO inhibitors with identical beta-lactamase inhibitory profiles covering KPC, AmpC, and OXA-48; the only difference is that sulbactam-durlobactam uses sulbactam as the partner while ceftazidime-avibactam uses ceftazidime; both combinations are approved for both CRAB and KPC-CRE
• D) Sulbactam-durlobactam and ceftazidime-avibactam are interchangeable for all CRE indications; sulbactam-durlobactam was developed specifically because ceftazidime-avibactam is more expensive, and the FDA approved sulbactam-durlobactam as a cost-effective biosimilar alternative for the same indications
• E) Sulbactam-durlobactam's clinical activity is specifically tied to sulbactam's unique direct antibacterial activity against Acinetobacter baumannii through PBP1/PBP3 binding; this anti-Acinetobacter PBP activity is not present against Klebsiella pneumoniae or E. coli regardless of which beta-lactamase inhibitor is paired with sulbactam; sulbactam-durlobactam is therefore indicated for CRAB specifically and is not a replacement for KPC-CRE or NDM-CRE therapy, for which ceftazidime-avibactam, meropenem-vaborbactam, or aztreonam-avibactam remain the appropriate regimens

24. [CASE 6 — QUESTION 4] Continuing with the same patient. Sulbactam-durlobactam is working well clinically. The ICU pharmacist reviews monitoring parameters for this patient who has developed acute kidney injury (AKI) during the ICU stay, with creatinine rising from baseline. The pharmacist notes that both sulbactam and durlobactam are primarily renally eliminated and that dose adjustment guidance for renal impairment must be applied. An ICU nurse asks what the most important pharmacokinetic concern is for a patient developing AKI while on sulbactam-durlobactam. Which of the following best identifies the primary pharmacokinetic concern and the appropriate management response?

• A) The primary concern is that AKI reduces hepatic clearance of sulbactam's active glucuronide metabolite; as AKI progresses, this metabolite accumulates and competitively inhibits durlobactam's OXA-23 enzyme binding, reducing the combination's anti-CRAB activity; the dose of durlobactam should be increased proportionally as renal function declines to overcome this competitive inhibition
• B) The primary concern is that AKI causes sulbactam to undergo alternative metabolism via CYP2C9, generating a hepatotoxic sulfoxide metabolite; daily liver function tests should be obtained and sulbactam discontinued if transaminases exceed three times the upper limit of normal during the AKI episode
• C) The primary concern is that developing AKI during CRAB bacteremia indicates treatment failure; AKI in CRAB-infected patients is always due to septic renal injury, and its development while on sulbactam-durlobactam requires immediate reassessment of microbiological response and consideration of adding colistin for synergy
• D) Both sulbactam and durlobactam are primarily renally eliminated with low protein binding; as AKI develops and GFR (glomerular filtration rate) falls, clearance of both components is reduced and plasma concentrations rise above those achieved at standard dosing in normal renal function; the prescribing information dose adjustment guidance for sulbactam-durlobactam based on creatinine clearance must be applied, reducing doses and potentially extending intervals to prevent accumulation while maintaining adequate time above MIC with the lower but appropriately timed doses
• E) The primary concern is that AKI causes sulbactam to lose its direct PBP1 and PBP3 antibacterial activity against Acinetobacter; in patients with CrCl below 30 mL/min, sulbactam is filtered by the glomerulus but not secreted, resulting in urinary drug concentrations below the PBP binding threshold; this means sulbactam-durlobactam becomes pharmacologically inactive for CRAB infections in patients with advanced AKI

25. [CASE 7 — QUESTION 1] A 52-year-old man with liver cirrhosis Child-Pugh C is admitted with spontaneous bacterial peritonitis. Ascitic fluid and blood cultures grow Klebsiella pneumoniae. Carbapenem MICs return elevated above the susceptibility breakpoint. A comprehensive carbapenemase PCR panel for KPC, NDM, VIM, IMP, and OXA-48 returns negative. Whole-genome sequencing reveals mutations causing truncation of OmpK35 and OmpK36, and overexpression of CTX-M-15 (a class A ESBL) from a plasmid-associated promoter mutation. The patient's infectious disease team explains the resistance mechanism to the hepatology team. Which of the following best explains why carbapenem MICs are elevated in this isolate despite the negative carbapenemase PCR, and what mechanism is responsible?

• A) The carbapenemase PCR is falsely negative because CTX-M-15 is a class A enzyme that has evolved carbapenem-hydrolyzing activity through active site mutations not covered by standard KPC primers; the carbapenem resistance is mechanistically identical to KPC resistance and should be treated with the same agents used for KPC-CRE
• B) The negative PCR reflects true absence of a carbapenemase; however, CTX-M-15 at high expression levels functions as a low-level carbapenemase that produces intermediate carbapenem MICs through inefficient hydrolysis; at sufficiently high CTX-M-15 expression, the combined hydrolytic rate exceeds carbapenem influx even through intact porins, making the porin mutations a secondary contributor
• C) The negative PCR reflects true absence of all five tested carbapenemases; carbapenem resistance in this isolate is non-carbapenemase-mediated, arising from the synergy of OmpK35/OmpK36 porin loss (which reduces carbapenem influx across the outer membrane) and CTX-M-15 ESBL overexpression (which hydrolyzes the reduced amount of carbapenem that does enter the periplasm); neither mechanism alone achieves high-level resistance, but together they produce elevated carbapenem MICs without any carbapenemase enzyme
• D) The negative PCR indicates that this isolate harbors a novel class B metallo-beta-lactamase gene structurally divergent from NDM, VIM, and IMP that is not detected by current PCR probe sets; CTX-M-15 and the porin mutations are coincidental findings; treatment should follow NDM-CRE protocols using aztreonam-avibactam until confirmatory whole-genome sequencing for novel class B enzymes is available
• E) The negative PCR is expected because porin loss mutations are not detected by carbapenemase PCR; OmpK35/OmpK36 truncation alone produces carbapenem MICs in the resistant range by completely blocking carbapenem outer membrane penetration; CTX-M-15 is a bystander ESBL with no role in the carbapenem resistance phenotype of this isolate

26. [CASE 7 — QUESTION 2] Continuing with the same patient. Susceptibility testing returns: resistant to all carbapenems, resistant to ceftriaxone and cefepime, but susceptible to ceftazidime-avibactam with a low MIC. The infectious disease team selects ceftazidime-avibactam as definitive therapy. The hepatology team asks why ceftazidime-avibactam works when all carbapenems have failed, given that ceftazidime is a cephalosporin that should also be susceptible to ESBL hydrolysis. Which of the following best explains the mechanism by which ceftazidime-avibactam retains activity against this non-carbapenemase CRE?

• A) Ceftazidime is inherently resistant to CTX-M-15 hydrolysis because its bulky ceftazidime-specific R1 side chain sterically blocks CTX-M-15 access to the ceftazidime beta-lactam carbonyl; avibactam is added purely to inhibit any residual AmpC activity; the combination works because ceftazidime's natural CTX-M-15 resistance overcomes the ESBL component of resistance independently of avibactam
• B) Ceftazidime-avibactam works because avibactam's DBO scaffold restores OmpK35 and OmpK36 porin expression in this isolate by inhibiting the transcriptional repressor that silenced the porin genes in response to carbapenem exposure; with restored porin expression, both ceftazidime and carbapenems would regain susceptibility, but ceftazidime is used as the partner because of its lower CNS toxicity
• C) Ceftazidime-avibactam works because ceftazidime does not require OmpK35 or OmpK36 for outer membrane penetration; it enters the Klebsiella periplasm exclusively through the BamA outer membrane assembly protein, which is not affected by the porin mutations; once in the periplasm, avibactam inhibits CTX-M-15 and ceftazidime reaches its PBP targets
• D) Ceftazidime is indeed a CTX-M-15 substrate that would be hydrolyzed if CTX-M-15 were uninhibited; avibactam inhibits CTX-M-15 (a class A serine ESBL) by forming a reversible covalent carbamyl ester with its catalytic serine, eliminating the enzymatic hydrolysis component of resistance; with CTX-M-15 inhibited, the remaining resistance mechanism (porin loss alone) reduces ceftazidime entry but does not prevent bactericidal periplasmic concentrations from accumulating at standard dosing; ceftazidime's susceptibility is restored by removing the enzymatic component of the combined resistance mechanism
• E) Ceftazidime-avibactam works because all Klebsiella pneumoniae with OmpK35/OmpK36 porin mutations simultaneously lose the ability to produce CTX-M-15 at the protein level, even when the CTX-M-15 gene is present; the porin mutations create a pleiotropic regulatory effect that reduces periplasmic enzyme folding; avibactam is therefore inhibiting a non-functional enzyme and it is the inherent ceftazidime stability that provides the antibacterial activity

27. [CASE 7 — QUESTION 3] Continuing with the same patient. The patient is started on ceftazidime-avibactam and improves over the first 5 days. The hepatology team notes that this patient has Child-Pugh C cirrhosis with ongoing ascites, will likely require a prolonged treatment course (minimum 4 weeks), and has a high risk for treatment-related complications. The infectious disease team emphasizes the need for clinical and microbiological monitoring during prolonged ceftazidime-avibactam therapy. Which of the following best identifies the most important on-therapy monitoring concern specific to ceftazidime-avibactam in the context of prolonged treatment for CRE?

• A) On-therapy emergence of avibactam resistance is documented in up to 15% of patients treated with ceftazidime-avibactam for extended courses (best characterized as KPC active-site mutations such as D179Y/D179N, with analogous resistance evolution described in other serine-beta-lactamase producers including CTX-M-type ESBLs); repeat blood and fluid cultures with susceptibility testing should be performed if the patient has clinical deterioration after initial improvement, to detect resistance emergence early and allow timely switching to an alternative active agent before septic deterioration
• B) The primary on-therapy concern is avibactam nephrotoxicity; avibactam accumulates in renal proximal tubular cells during prolonged treatment and causes a dose-dependent crystalline nephropathy similar to acyclovir; serum creatinine and urinalysis for crystalluria should be monitored every 48 hours during therapy exceeding 2 weeks
• C) The primary on-therapy concern is ceftazidime-induced seizures; ceftazidime at the doses used for CRE (2 g IV every 8 hours) produces GABA-A receptor antagonism similar to imipenem; the seizure risk is amplified in cirrhotic patients due to hepatic encephalopathy-associated reduction in GABAergic inhibitory reserve, requiring daily neurological assessments and prophylactic levetiracetam for courses exceeding 7 days
• D) The primary on-therapy monitoring concern is ceftazidime-avibactam-induced dysbiosis causing Clostridioides difficile colitis; prolonged ceftazidime use eliminates all gut flora and avibactam's DBO ring is specifically toxic to Clostridioides difficile competitive exclusion flora; fecal microbiome transplant should be planned prophylactically for any ceftazidime-avibactam course exceeding 14 days
• E) The primary on-therapy concern is that avibactam induces hepatic CYP3A4 and reduces the efficacy of any concomitant medications metabolized by CYP3A4; in cirrhotic patients with reduced baseline CYP3A4 activity, avibactam's enzyme induction causes unpredictable increases in CYP3A4 expression that paradoxically overshoot normal function, requiring therapeutic drug monitoring for all CYP3A4 substrates the patient receives

28. [CASE 7 — QUESTION 4] Continuing with the same patient. At day 14 of ceftazidime-avibactam, repeat cultures of blood and ascitic fluid are sterile, ascites volume has decreased with diuretic therapy and large-volume paracentesis, and the patient is clinically improved with normalization of fever and leukocytosis. The team considers de-escalation or transition. The hepatology team asks whether the patient can be transitioned to an oral agent to complete therapy. Integrating the available oral options and the pharmacological properties of the agents that have been used, which of the following best describes the approach to antibiotic de-escalation and oral step-down in this patient with non-carbapenemase CRE SBP (spontaneous bacterial peritonitis)?

• A) The patient should be transitioned to oral ertapenem to complete therapy, as ertapenem's oral prodrug formulation achieves 60% bioavailability for ESBL-producing Enterobacteriaceae; this step-down eliminates the need for IV access while maintaining carbapenem-class coverage for the non-carbapenemase CRE
• B) The patient can be stepped down to oral ceftazidime-avibactam tablets for the remainder of therapy; oral bioavailability of the ceftazidime-avibactam combination is approximately 55% when taken with food, achieving plasma concentrations above the MIC for the non-carbapenemase CRE isolate at standard oral dosing
• C) Step-down to an oral agent is generally not feasible for non-carbapenemase CRE SBP because no currently approved oral antibiotic achieves sufficient systemic concentrations to treat Enterobacteriaceae with elevated carbapenem MICs and ESBL co-production; the patient should complete the full 4-week intended course with IV ceftazidime-avibactam, maintaining IV access for the duration
• D) The patient should be stepped down to oral trimethoprim-sulfamethoxazole, which achieves near-100% bioavailability and provides reliable coverage of non-carbapenemase CRE because its dihydrofolate reductase inhibitory mechanism is unaffected by beta-lactamase expression or outer membrane porin mutations; susceptibility to trimethoprim-sulfamethoxazole should be confirmed first
• E) No currently approved oral beta-lactam achieves adequate systemic concentrations to treat non-carbapenemase CRE with elevated carbapenem MICs; oral step-down for non-carbapenemase CRE infections requires susceptibility testing to identify whether the isolate has retained susceptibility to non-beta-lactam oral agents (fluoroquinolones, trimethoprim-sulfamethoxazole, or fosfomycin depending on the infection site and isolate susceptibility pattern); treatment duration should follow evidence-based guidance for SBP and bacteremia, typically 5–14 days from culture sterilization for SBP with confirmed source control, and oral step-down is possible if susceptibility to an orally bioavailable non-beta-lactam agent is confirmed